HRP20010444A2 - BENZISOXAZOLES AND PHENONES AS <F128M>a<F255D><->2<P>-ANTAGONISTS - Google Patents

BENZISOXAZOLES AND PHENONES AS <F128M>a<F255D><->2<P>-ANTAGONISTS Download PDF

Info

Publication number
HRP20010444A2
HRP20010444A2 HR20010444A HRP20010444A HRP20010444A2 HR P20010444 A2 HRP20010444 A2 HR P20010444A2 HR 20010444 A HR20010444 A HR 20010444A HR P20010444 A HRP20010444 A HR P20010444A HR P20010444 A2 HRP20010444 A2 HR P20010444A2
Authority
HR
Croatia
Prior art keywords
formula
compounds
compound according
mixture
alkyl
Prior art date
Application number
HR20010444A
Other languages
English (en)
Croatian (hr)
Inventor
Ludo Edmond Josephine Kennis
Josephus Carolus Mertens
Serge
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP20010444A2 publication Critical patent/HRP20010444A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20010444A 1998-12-21 1999-12-14 BENZISOXAZOLES AND PHENONES AS <F128M>a<F255D><->2<P>-ANTAGONISTS HRP20010444A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98204358 1998-12-21
PCT/EP1999/010054 WO2000037466A1 (en) 1998-12-21 1999-12-14 BENZISOXAZOLES AND PHENONES AS α2-ANTAGONISTS

Publications (1)

Publication Number Publication Date
HRP20010444A2 true HRP20010444A2 (en) 2002-06-30

Family

ID=8234508

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010444A HRP20010444A2 (en) 1998-12-21 1999-12-14 BENZISOXAZOLES AND PHENONES AS <F128M>a<F255D><->2<P>-ANTAGONISTS

Country Status (30)

Country Link
US (1) US6576640B1 (de)
EP (1) EP1140934B1 (de)
JP (1) JP4717216B2 (de)
KR (2) KR100657540B1 (de)
CN (1) CN1154646C (de)
AR (1) AR021924A1 (de)
AT (1) ATE251622T1 (de)
AU (1) AU765751B2 (de)
BG (1) BG65162B1 (de)
BR (1) BR9916427A (de)
CA (1) CA2355716C (de)
CZ (1) CZ294532B6 (de)
DE (1) DE69911995T2 (de)
EA (1) EA003606B1 (de)
EE (1) EE200100329A (de)
ES (1) ES2209553T3 (de)
HK (1) HK1045686B (de)
HR (1) HRP20010444A2 (de)
HU (1) HUP0104812A3 (de)
ID (1) ID28967A (de)
IL (2) IL143830A0 (de)
NO (1) NO317892B1 (de)
NZ (1) NZ511411A (de)
PL (1) PL196958B1 (de)
SK (1) SK285560B6 (de)
TR (1) TR200101813T2 (de)
TW (1) TWI229673B (de)
UA (1) UA71938C2 (de)
WO (1) WO2000037466A1 (de)
ZA (1) ZA200105067B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404679A2 (de) 2001-07-05 2004-04-07 PHARMACIA &amp; UPJOHN COMPANY (hetero)aryl substituierte benzofuranen als 5-ht liganden
ATE521593T1 (de) * 2002-04-03 2011-09-15 Orion Corp Verwendung eines alfa2-adrenorezeptorantagonisten bei mit dem zns zusammenhängenden erkrankungen
WO2005100355A1 (ja) 2004-04-12 2005-10-27 Taisho Pharmaceutical Co., Ltd. 環状アミン化合物
KR20080034171A (ko) * 2005-07-28 2008-04-18 브리스톨-마이어스 스큅 컴퍼니 세로토닌 수용체 효능제 및 길항제로서의 치환된테트라히드로-1ｈ-피리도[4,3,ｂ]인돌
CN117327065A (zh) * 2022-06-23 2024-01-02 北京大学 作为多巴胺d2/3受体调节剂的咔唑类衍生物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3419568A (en) * 1966-12-07 1968-12-31 Abbott Lab Derivatives of 1,2,3,4-tetrahydro-5h-pyrido[4,3b]indoles
US3382250A (en) * 1966-12-07 1968-05-07 Abbott Lab Aroylalkyl derivatives of 1, 2, 3, 4-tetrahydro-5h-pyrido[4, 3b]indoles
US3718657A (en) * 1970-12-03 1973-02-27 Abbott Lab Certain-2-substituted-1,2,3,4-tetrahydro-beta or gamma carbolines
JPS4729395U (de) * 1971-04-26 1972-12-04
US4001263A (en) * 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
AR207799A1 (es) * 1974-04-01 1976-10-29 Pfizer Procedimiento para preparar azaciclo(3,4-a)-n-fenilindoles-2-substituidos
US4224329A (en) * 1979-01-23 1980-09-23 Pfizer Inc. 2-Substituted-trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indoles
FR2570701B1 (fr) * 1984-09-27 1987-05-22 Synthelabo Derives de furo(3,2-c)pyridines, leur preparation et leur application en therapeutique
DE3522959A1 (de) * 1985-06-27 1987-01-08 Merck Patent Gmbh Indolderivate
US4985422A (en) * 1988-04-27 1991-01-15 Glaxo Group Limited Lactam derivatives
WO1994008040A1 (en) * 1992-09-25 1994-04-14 Synaptic Pharmaceutical Corporation Dna encoding human alpha 1 adrenergic receptors and uses thereof
US5403847A (en) 1992-11-13 1995-04-04 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperlasia
US5508306A (en) * 1992-11-13 1996-04-16 Synaptic Pharmaceutical Corporation Aromatic amine derivatives
UA52681C2 (uk) * 1997-04-08 2003-01-15 Янссен Фармацевтика Н.В. Похідні 1,2,3,4-тетрагідро-бензофуро[3,2,-c]піридину, спосіб їх одержання та фармацевтична композиція на їх основі

Also Published As

Publication number Publication date
KR20060093139A (ko) 2006-08-23
PL196958B1 (pl) 2008-02-29
CN1331692A (zh) 2002-01-16
KR20010075650A (ko) 2001-08-09
AU2432700A (en) 2000-07-12
EP1140934B1 (de) 2003-10-08
IL143830A (en) 2007-07-24
NO20012783D0 (no) 2001-06-06
AR021924A1 (es) 2002-09-04
NO20012783L (no) 2001-06-06
IL143830A0 (en) 2002-04-21
HUP0104812A2 (hu) 2002-04-29
JP2002533341A (ja) 2002-10-08
BG105521A (en) 2001-12-29
SK285560B6 (sk) 2007-03-01
BR9916427A (pt) 2001-09-04
CA2355716C (en) 2010-05-18
PL348421A1 (en) 2002-05-20
SK8582001A3 (en) 2001-12-03
AU765751B2 (en) 2003-09-25
EE200100329A (et) 2002-08-15
ES2209553T3 (es) 2004-06-16
EA200100709A1 (ru) 2001-12-24
HK1045686B (zh) 2005-04-01
CZ20012120A3 (cs) 2001-10-17
WO2000037466A1 (en) 2000-06-29
NZ511411A (en) 2002-12-20
ATE251622T1 (de) 2003-10-15
EP1140934A1 (de) 2001-10-10
US6576640B1 (en) 2003-06-10
EA003606B1 (ru) 2003-06-26
DE69911995D1 (de) 2003-11-13
UA71938C2 (en) 2005-01-17
HK1045686A1 (en) 2002-12-06
ID28967A (id) 2001-07-19
DE69911995T2 (de) 2004-09-02
CN1154646C (zh) 2004-06-23
JP4717216B2 (ja) 2011-07-06
ZA200105067B (en) 2002-06-20
TWI229673B (en) 2005-03-21
HUP0104812A3 (en) 2003-12-29
TR200101813T2 (tr) 2001-12-21
CA2355716A1 (en) 2000-06-29
KR100657540B1 (ko) 2006-12-14
CZ294532B6 (cs) 2005-01-12
NO317892B1 (no) 2004-12-27
BG65162B1 (bg) 2007-04-30

Similar Documents

Publication Publication Date Title
JP4590101B2 (ja) α２−アンタゴニストとしての三環性Δ３−ピペリジン類
HRP20010444A2 (en) BENZISOXAZOLES AND PHENONES AS &lt;F128M&gt;a&lt;F255D&gt;&lt;-&gt;2&lt;P&gt;-ANTAGONISTS
US6352999B1 (en) Tricylic delta 3-piperidines as pharmaceuticals
JP4580555B2 (ja) α２アンタゴニストとしてのベンゾチエノ［３，２−ｃ］ピリジン類
MXPA01006353A (en) Benzisoxazoles and phenones as alpha 2-antagonists
MXPA01003512A (en) TRICYCLIC&amp;Dgr;3-PIPERIDINES AS PHARMACEUTICALS
MXPA01003514A (en) BENZOTHIENO[3,2-c]PYRIDINES AS&amp;agr;2
HK1038009B (en) Tricyclic delta3-piperidines as pharmaceuticals

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20061117

Year of fee payment: 8

OBST Application withdrawn